Investing
1489 Articles
Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) has had its share of trouble in 2011, but perhaps the expiring patent on…
It has been a long time coming, and now many patients will be able to switch to a generic. Pfizer…
The EU continues to work on its bailout fund and may ask the IMF for help. (Reuters) American Airlines parent…
Pfizer Inc. (NYSE: PFE) has a big day ahead of it. While it has been known for years, it is…
It now costs about $1 billion to get a new drug to market, or, if a company is unlucky, $1…
The supercommittee appears unlikely to settle on a deficit agreement. (Reuters) A senior Chinese official says he expects the global…
Some companies just want to keep bringing on new share buybacks whether they work or not. Some are to stop…
The economic choppiness is coming to a head with the age of dividend hikes. The pressure is going to remain…
George Papandreou convinces the Greek cabinet of the virtues of a national referendum on budget cuts, but he now faces…
The markets are beyond jittery. From a massively overbought market discounting a recession entirely back to a market dominated by the…
Earnings season is still running strong and the economic readings keep coming out as well. As we come to the…
Short sellers moved out of stocks that have fallen recently. Perhaps they believe there will be a large rally in…
Novartis (NYSE: NVS) said it would cut 2,000 workers and outsource some functions to companies that will do the work…
A company can spend billions of dollars on R&D and get little respect as an innovator. Even though that is…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better…
Our top personal finance-related articles today. Your wallet will thank you later.